Delivery Order SPE2DB24D2003-SPE2DB25FXLZ6
Award Date 8/22/25
Potential Completion Date 8/25/25
Potential Value $3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, valued at $52,706.28, is scheduled for completion by August 12, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. The contract received no set-aside...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication. This firm fixed-price delivery order, valued at $57,804.94, represents a non-competitive award under a larger contract vehicle and is scheduled for completion by August 8, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used primarily for treating rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order has a ceiling value of $2,598.96 and an ultimate completion date of August 20, 2025. The award was made without a set-aside designation, indicating it was awarded through open competition. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a firm fixed-price delivery order valued at $12,837.62 for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This contract award, issued on July 30, 2025, represents a non-competitive child delivery order under an existing indefinite delivery contract vehicle. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 31, 2025. HUMIRA is a widely used...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL doses. This is a firm fixed price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. HUMIRA is a widely...
- The Defense Logistics Agency awarded a delivery order valued at $1,529.47 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL pharmaceutical supply. This contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,497.68 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication prescribed for various autoimmune conditions including...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA Pen 40mg/4mL (2 pens) with a ceiling value of $26,615.29. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. HUMIRA...